Samuel Agresta - 16 Aug 2023 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief Medical Officer
Signature
/s /Allan Reine, M.D., Attorney-in-Fact
Issuer symbol
FHTX
Transactions as of
16 Aug 2023
Net transactions value
-$1,410,175
Form type
4
Filing time
18 Aug 2023, 16:03:38 UTC
Previous filing
30 Jan 2023
Next filing
13 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FHTX Common Stock Options Exercise $1,158,025 +311,297 $3.72 311,297 16 Aug 2023 Direct
transaction FHTX Common Stock Sale $2,568,200 -311,297 -100% $8.25 0 16 Aug 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Options Exercise $0 -311,297 -100% $0.000000* 0 16 Aug 2023 Common Stock 311,297 $3.72 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until fully vested.